Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DOHXR
ADC Name
Anti-MSLN mAb 6A4-IIIa-08
Synonyms
Anti-MSLN-mAb-6A4-IIIa-08
   Click to Show/Hide
Organization
Bristol Myers Squibb Co.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Drug-to-Antibody Ratio
3
Antibody Name
Anti-MSLN mAb 6A4
  Antibody Info 
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Anti-MSLN mAb 6A4-IIIa-08 linker
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
60
nM
CVCL_1051
Renal cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 60.00 nM Negative MSLN expression (MSLN-)
Method Description
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.

   Click to Show/Hide
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
References
Ref 1 Benzodiazepine dimers, conjugates thereof, and methods of making and using.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.